

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

SERIAL NO.: 09/039,957

FILING DATE: March 16, 1998

ENTAIL INFORMATION
NT

0195

FEB 09 2004


DIET & TRADEMARK OFFICE

[illegible][illegible]

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>170</i>	C23	Bosanquet, Andrew G., "Short-term In Vitro Drug Sensitivity Tests for Cancer Chemotherapy. A Summary of Correlations of Test result With Both Patient Response and Survival", Forum, vol. 4, no. 2, pp. 179-195 (1994).
<i>170</i>	C24	Furuehauf, J.P. "In Vitro Assay-Assisted Treatment selection for Women with Breast or Ovarian Cancer", Endocrine-Related Cancer, vol. 9, pp. 171-182 (2002).
<i>170</i>	C25	McGuire, William L. <i>et al.</i> , "In Vitro Assays to Predict Drug Sensitivity and Drug Resistance", Breast Cancer Research and Treatment, vol. 12, pp. 7-21 (1988).
<i>170</i>	C26	Robert, Jacques, "Chemosensitivity Testing- Prediction of Response to Anticancer Drugs Using In Vitro Assays", Electronic Journal of Oncology, vol. 2, pp. 198-210 (1999).

EXAMINER


DATE CONSIDERED



Express Mail Mailing Label No. EV 375067812 US

SHEET 1 OF 2

FORM PTO - 1449				ATTORNEY DOCKET NO.: PTI-002					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Kornblith					
				SERIAL NO.: 09/039,957					
				FILING DATE: March 16, 1998 GROUP: 1651					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
RG	A17	4,559,299	12/17/85	Rotman			02/04/83		
	A18	4,668,618	05/26/87	Thornthwaite			01/30/84		
	A19	4,816,395	03/28/89	Hancock <i>et al.</i>			12/19/85		
	A20	5,403,574	04/04/95	Piwnica-Worms			06/26/92		
	A21	5,705,270	01/06/98	Soon-Shiong <i>et al.</i>			06/07/95		
	A22	6,111,092	08/29/00	Williamson			06/03/98		
	A23	6,664,062 B1	12/16/03	Stanton			09/24/01		
	A24	2002/0168679 A1	11/14/02	Naus <i>et al.</i>			06/11/98		
	A25	2002/0192638 A1	12/19/02	Kornblith			07/26/02		
	A26	2004/0023375 A1	02/05/04	Kornblith <i>et al.</i>			07/30/02		
	A27	2004/0072722 A1	04/15/04	Kornblith <i>et al.</i>			01/02/03		
✓	A28	2004/0086888 A1	05/06/04	Kornblith <i>et al.</i>			10/18/01		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
RG	B1	WO96/10742	04/11/96	PCT			09/29/95	N	Y
RG	B2	WO98/02038	01/22/98	PCT			07/10/97	N	Y
RG	B3	WO02/33117A2	04/25/02	PCT			10/18/01	N	Y
RG	B4	WO2004/035833A1	04/29/04	PCT			10/10/03	N	Y
RG	B5	WO2004/015065A2	02/19/04	PCT			07/30/03	N	Y
EXAMINER				DATE CONSIDERED					
RG / R. J. R. M. D.				11/9/04					



SHEET 2 OF 2

FORM PTO - 1449		ATTORNEY DOCKET NO.: PTI-002	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Kornblith	
		SERIAL NO.: 09/039,957	
		FILING DATE: March 16, 1998 GROUP: 1651	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
<i>RG</i>	C23	Bosanquet, A.G., "Short-term <i>in vitro</i> drug sensitivity tests for cancer chemotherapy. A summary of correlations of test result with both patient response and survival," <i>Forum</i> 4(2):179-195 (1994).	
<i>RG</i>	C24	Fruehauf, J.P., "In vitro assay-assisted treatment selection for women with breast or ovarian cancer," <i>Endocrine-Related Cancer</i> 9:171-182 (2002).	
<i>RG</i>	C25	McGuire <i>et al.</i> , "In vitro assays to predict drug sensitivity and drug resistance: A panel discussion," <i>Breast Cancer Research and Treatment</i> 12:7-21 (1988).	
<i>RG</i>	C26	Robert, J., "Chemosensitivity testing: Prediction of response to anticancer drugs using in vitro assays," <i>Electronic Journal of Oncology</i> 2:198-205 (1999).	
<i>RG</i>	C27	Kornblith, P., "Role of Tissue Culture in Prediction of Malignancy," <i>Clinical Neurosurgery</i> , Vol. 25, pp. 346-376 (1978).	
<i>RG</i>	C28	Freshney, R.I., <i>Culture of Animal Cells: A Manual of Basic Technique</i> , 2nd edition, pp. 107, 124-126, 179, 233-234, 290 (1987).	
<i>RG</i>	C29	Guo <i>et al.</i> , "Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports," <i>Nucleic Acids Research</i> 22(24):5456-5465 (1994).	
<i>RG</i>	C30	Pfost <i>et al.</i> , "A SNPshot: pharmacogenetics and the future of drug therapy," <i>TIBTECH</i> 18:334-338 (August, 2000).	
<i>RG</i>	C31	Raju, G.C., "The histological and immunohistochemical evidence of squamous metaplasia from the myoepithelial cells in the breast," <i>Histopathology</i> 17(3):272-275 (1990).	
<i>RG</i>	C32	Stephens, J.C., "Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics," <i>Molecular Diagnosis</i> 4(4):309-317 (1999).	
<i>RG</i>	C33	Tannock <i>et al.</i> , <i>The Basic Science of Oncology</i> , 2nd edition, pp. 247-248, 261-265, 303-306 (1992).	
<i>RG</i>	C34	Becton-Dickinson Catalog, Anti-Cytokeratin (CAM 5.2) Reagent, pp. 1-11 (1997).	
<i>RG</i>	C35	Boehringer Mannheim Catalog, Anti-Cytokeratin AE1/AE3, (1996).	
<i>RG</i>	C36	DAKO Catalog, Specification Sheet for Monoclonal Mouse Anti-Human Epithelial Membrane Antigen, pp. 1-2 (1996).	
EXAMINER	<i>RG1702112</i>		DATE CONSIDERED <i>11/9/04</i>

3067890